Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505770 | 1.00 | HDAC1 (0.37) | HDAC1ALDH1A1CA12CA1CA2 | |
| SCHEMBL26118022 | 0.78 | HDAC1 (0.35) | HDAC1CA2CSF1RLRRK2KMT2A | |
| SCHEMBL26118027 | 0.78 | HDAC1 (0.35) | HDAC1CA2CSF1RLRRK2KMT2A | |
| SCHEMBL4955773 | 0.71 | — | — | |
| SCHEMBL15577218 | 0.69 | — | — | |
| Bicarbonate SCHEMBL28121604 | 0.69 | KMT2A (0.34) | HDAC1CSF1RKMT2ACD38TDP1 | |
| SCHEMBL41619 | 0.69 | GAA (0.53) | ALDH1A1HPGDKMT2ALMNATDP1 | |
| SCHEMBL41618 | 0.69 | GAA (0.53) | ALDH1A1HPGDKMT2ALMNATDP1 | |
| SCHEMBL199861 | 0.69 | GAA (0.53) | ALDH1A1HPGDKMT2ALMNATDP1 | |
| Benzene SCHEMBL27553763 | 0.69 | GAA (0.53) | ALDH1A1HPGDKMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | disclosed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING B.V. (NL) | 2024-03-14 | — | — | US | disclosed |
| WO-2024011333-A1 | METHOD OF TREATING SKELETAL MUSCLE STEM CELL PATHOLOGIC DYSFUNCTION | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-01-18 | — | — | WO | disclosed |
| EP-3666258-B1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING BV (NL) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | disclosed |
| CN-112773765-A | Methods of treating prader-willi syndrome | 辉凌公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20200129584-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING B.V. (NL) | 2020-04-30 | — | — | US | disclosed |
| US-10441627-B2 | Method of treating prader-willi syndrome | FERRING B.V. (NL) | 2019-10-15 | — | — | US | disclosed |
| US-20170326200-A1 | Method of Treating Prader-Willi Syndrome | FERRING B.V. (NL) | 2017-11-16 | — | — | US | disclosed |
| EP-3193907-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | Ferring BV (NL) | 2017-07-26 | — | — | EP | disclosed |
| CN-102656183-B | Oxytocin receptor agonist | FERRING B.V. (NL) | 2016-03-30 | — | — | CN | disclosed |
| WO-2016044131-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING B.V. (NL) | 2016-03-24 | — | — | WO | disclosed |
| US-8748564-B2 | Oxytocin receptor agonists | FERRING B.V. (NL) | 2014-06-10 | — | — | US | disclosed |
| EP-2491052-A2 | OXYTOCIN RECEPTOR AGONISTS | Ferring International Center S.A. (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120214733-A1 | OXYTOCIN RECEPTOR AGONISTS | FERRING INTERNATIONAL CENTER S.A. (CH) | 2012-08-23 | — | — | US | disclosed |
| WO-2011035330-A2 | OXYTOCIN RECEPTOR AGONISTS | FERRING INTERNATIONAL CENTER S.A. (CH) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441627-B2 | Method of treating prader-willi syndrome | OXTR, MC2R, AVPR2 | HDAC1 644/4885ALDH1A1 3379/4885CA12 3252/4885 |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | APLNR, AP3D1, AP3B1 | HDAC1 1999/4885ALDH1A1 2222/4885CA12 1670/4885 |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | OXTR, MC2R, AVPR2 | HDAC1 644/4885ALDH1A1 3379/4885CA12 3252/4885 |
| US-20170326200-A1 | Method of Treating Prader-Willi Syndrome | OXTR, MC2R, AVPR2 | HDAC1 644/4885ALDH1A1 3379/4885CA12 3252/4885 |
| US-20200129584-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | OXTR, MC2R, AVPR2 | HDAC1 644/4885ALDH1A1 3379/4885CA12 3252/4885 |
| US-20120214733-A1 | OXYTOCIN RECEPTOR AGONISTS | OXTR, PRLHR, AVPR1A | HDAC1 2609/4885ALDH1A1 2418/4885CA12 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.